Back to today’s briefing

Story perspectives

FDA Removes Semaglutide: Patients Face Soaring Drug Costs

6/26/2025

25 4

Summary

Story summary

The FDA's decision to remove semaglutide from its shortage list sends ripples through North Texas pharmacies that depended on compounded versions for income. With brand-name GLP-1 drugs priced between $900 and $1,500 monthly, patients are left grappling with exorbitant costs, raising fears that some may turn to unregulated online options, jeopardizing their safety with counterfeit medications.

1 of 1

Story summary

The FDA's decision to remove semaglutide from its shortage list sends ripples through North Texas pharmacies that depended on compounded versions for income. With brand-name GLP-1 drugs priced between $900 and $1,500 monthly, patients are left grappling with exorbitant costs, raising fears that some may turn to unregulated online options, jeopardizing their safety with counterfeit medications.